University of Basel, Switzerland.
Swiss Tropical and Public Health Institute, Basel, Switzerland.
Swiss Med Wkly. 2022 Mar 24;152:w30135. doi: 10.4414/smw.2022.w30135. eCollection 2022 Mar 14.
Multimorbidity is a growing global health problem, resulting in an increased perioperative risk for surgical patients. Data on both the prevalence of multimorbidity and its impact on perioperative outcome are limited. The American Society of Anesthesiologists (ASA) classification uses only the single most severe systemic disease to define the ASA class and ignores multimorbidity. This study aimed to assess the number and type of all anaesthesia-relevant comorbidities and to analyse their impact on outcome and hospital costs.
This cohort study is nested in the ClassIntra® validation study and includes only patients enrolled at the University Hospital of Basel. Approximately 30 patients per surgical discipline undergoing any type of in-hospital surgery were followed up until hospital discharge to record all intra- and postoperative adverse events. In addition, the type and severity of all perioperatively relevant comorbidities were extracted from the electronic medical record according to a predefined list. The primary endpoint was the number of all anaesthesia-relevant comorbidities by ASA class. Using structural equation models, the direct and indirect effects of comorbidities on costs were estimated after adjustment for the ASA class and further relevant confounders and mediators.
Of 320 enrolled patients, 27 were ASA I (8%), 150 ASA II (47%), 116 ASA III (36%) and 27 ASA IV (8%). The median number of comorbidities per patient was 5 (range 0-18), this number significantly increasing with higher ASA class: 1 comorbidity (95% CI 0.0-2.0) in ASA I, 4 comorbidities (3.8-4.2) in ASA II, 9 (8.1-9.9) in ASA III and 12 (10-14) in ASA IV patients. Independent of ASA class, each additional comorbidity increased hospital costs by EUR 1,198 (95% CI 288-2108) with almost identical proportions of direct and indirect effects. The number of anaesthesia-relevant comorbidities also increased postoperative complications and postoperative length of hospital stay.
Multimorbidity in perioperative patients is highly prevalent and has a relevant impact on hospital costs, independent of the ASA class. Incorporating multimorbidity into the ASA classification might be warranted to improve its predictive ability and support adequate reimbursement.
多种并存疾病是一个日益严重的全球性健康问题,导致手术患者的围手术期风险增加。有关多种并存疾病的患病率及其对围手术期结果的影响的数据有限。美国麻醉医师学会(ASA)分类仅使用最严重的单一系统性疾病来定义 ASA 类别,而忽略了多种并存疾病。本研究旨在评估所有与麻醉相关的并存疾病的数量和类型,并分析其对结果和医院费用的影响。
该队列研究嵌套在 ClassIntra®验证研究中,仅包括在巴塞尔大学医院登记的患者。每个手术科室大约有 30 名接受任何类型院内手术的患者,在出院前进行随访,以记录所有围手术期不良事件。此外,根据预定义的清单,从电子病历中提取所有围手术期相关并存疾病的类型和严重程度。主要终点是根据 ASA 类别和进一步的相关混杂因素和调节剂,评估所有与麻醉相关的并存疾病的数量。使用结构方程模型,在调整 ASA 类别和其他相关混杂因素和调节剂后,估计并存疾病对成本的直接和间接影响。
在 320 名入组患者中,27 名患者为 ASA I(8%),150 名患者为 ASA II(47%),116 名患者为 ASA III(36%),27 名患者为 ASA IV(8%)。每位患者的平均并存疾病数量为 5 种(范围 0-18),随着 ASA 类别增加而显著增加:ASA I 患者 1 种并存疾病(95%CI 0.0-2.0),ASA II 患者 4 种并存疾病(3.8-4.2),ASA III 患者 9 种并存疾病(8.1-9.9),ASA IV 患者 12 种并存疾病(10-14)。独立于 ASA 类别,每增加一种并存疾病,医院费用增加 1198 欧元(95%CI 288-2108),直接和间接影响的比例几乎相同。与麻醉相关的并存疾病数量也增加了术后并发症和术后住院时间。
围手术期患者的多种并存疾病患病率很高,对医院费用有显著影响,独立于 ASA 类别。将多种并存疾病纳入 ASA 分类可能是必要的,以提高其预测能力并支持适当的报销。